The price of Perrigo Company plc (NYSE:PRGO) shares last traded on Wall Street rose 0.48% to $33.24.
Based on available information, 3 analysts follow Perrigo Company plc (NYSE:PRGO). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $49.00 and a low of $45.00, we find $47.00. Given the previous closing price of $33.08, this indicates a potential upside of 42.08 percent. PRGO stock price is now -1.90% away from the 50-day moving average and -5.93% away from the 200-day moving average. The market capitalization of the company currently stands at $4.56B.
Among analysts, 0 rate the stock a hold while 3 rate it a buy. Brokers who have rated the stock have averaged $47.00 as their price target over the next twelve months.
With the price target of $49, Canaccord Genuity recently initiated with Buy rating for Perrigo Company plc (NYSE: PRGO).
In other news, Parker Geoffrey M., Director bought 10,000 shares of the company’s stock on Jun 13. The stock was bought for $330,637 at an average price of $33.06. Upon completion of the transaction, the Director now directly owns 25,879 shares in the company, valued at $0.86 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 23, EVP & President CHCI Andersen Svend bought 2,900 shares of the business’s stock. A total of $96,902 was incurred on buying the stock at an average price of $33.41. This leaves the insider owning 68,741 shares of the company worth $2.28 million. Insiders disposed of 333,888 shares of company stock worth roughly $11.1 million over the past 1 year. A total of 1.06% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PRGO stock. A new stake in Perrigo Company plc shares was purchased by CANNELL & CO. during the first quarter worth $32,692,000. IONIC CAPITAL MANAGEMENT LLC invested $3,989,000 in shares of PRGO during the first quarter. In the first quarter, LOMBARD ODIER ASSET MANAGEMENT (USA) CORP acquired a new stake in Perrigo Company plc valued at approximately $3,281,000. HOLOCENE ADVISORS, LP acquired a new stake in PRGO for approximately $2,850,000. ORION PORTFOLIO SOLUTIONS, LLC purchased a new stake in PRGO valued at around $2,757,000 in the second quarter. In total, there are 470 active investors with 97.80% ownership of the company’s stock.
A candlestick chart of Perrigo Company plc (NYSE: PRGO) showed a price of $34.99 on Thursday morning. During the past 12 months, Perrigo Company plc has had a low of $30.78 and a high of $43.90. As of last week, the company has a debt-to-equity ratio of 0.85, a current ratio of 2.50, and a quick ratio of 1.40. The fifty day moving average price for PRGO is $33.80 and a two-hundred day moving average price translates $35.31 for the stock.
The latest earnings results from Perrigo Company plc (NYSE: PRGO) was released for Mar, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.45, beating analysts’ expectations of $0.42 by 0.03. This compares to -$0.01 EPS in the same period last year. The net profit margin was -3.10% and return on equity was -3.00% for PRGO. The company reported revenue of $1.18 billion for the quarter, compared to $1.07 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 9.98 percent. For the current quarter, analysts expect PRGO to generate $1.18B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 06/20/2023. Investors who held shares on 06/02/2023 were paid a $0.273 dividend. On an annualized basis, this represents a $1.09 dividend and a 3.29% percent yield. There was an ex-dividend date of 06/01/2023 for this dividend.
Perrigo Company plc(PRGO) Company Profile
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in Ireland, the United States, France, Belgium, China, the United Kingdom, Germany, Switzerland, Austria, Italy, Australia, Greece, and Spain. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The Consumer Self-Care Americas segment develops, manufacture, and markets self-care products including upper respiratory, pain and sleep-aids, digestive health, nutrition, healthy lifestyle, skincare, women’s health, and other products, as well as vitamins, minerals and supplements, and oral self-care in the United States and Canada. This segment offers its products under Burt’s Bees, Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, and Steripod brands. Consumer Self-Care International segment comprises consumer self-care product categories outside the U.S. and Canada, including branded products in Europe and Australia, and store brand products in the United Kingdom and parts of Europe and Asia, which develops, manufactures, markets, and distributes consumer self-care brands through a network of drug and grocery store retailers, e-commerce stores, and para-pharmacies in more than 29 countries, primarily in Europe. In addition, the company offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
